ALNYLAM PHARMACEUTICALS, INC. Collaboration Agreements
27 Contracts & Agreements
- Amendment No. 3 entered into as of August 1, 2024 to the Master Collaboration Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc (Filed With SEC on October 31, 2024)
- Amendment No. 2 to License and Collaboration Agreement, dated as of October 31, 2022 between the Registrant and The Medicines Company (Filed With SEC on February 23, 2023)
- License and Collaboration Agreement dated as of February 3, 2013 by and among The Medicines Company and the Registrant (Filed With SEC on February 23, 2023)
- Amendment to License and Collaboration Agreement, dated as of November 22, 2019 between the Registrant and The Medicines Company (Filed With SEC on February 13, 2020)
- Amendment No. 3 entered into as of April 8, 2019 to the Master Collaboration Agreement dated as of January 11, 2014, as amended by Amendment No. 1 and Amendment No. 2, including... (Filed With SEC on August 6, 2019)
- Amendment No. 2 entered into as of January 6, 2018 to the Master Collaboration Agreement dated as of January 11, 2014, as amended by Amendment No. 1, including certain Regional,... (Filed With SEC on May 4, 2018)
- AMENDMENTNUMBER ONE TO THE SECOND AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 9, 2015)
- AMENDMENT NO. 1 TO MASTER COLLABORATION AGREEMENT (Filed With SEC on November 9, 2015)
- AMENDMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 8, 2015)
- SECOND AMENDEDAND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 8, 2015)
- LICENSE AND COLLABORATION AGREEMENT by and between ALNYLAM PHARMACEUTICALS, INC. and THE MEDICINES COMPANY (Filed With SEC on May 7, 2013)
- EX-10.40 First Amendment to License and Collaboration Agreement entered into as of November 2, 2009 (Filed With SEC on February 26, 2010)
- EX-10.39 Collaboration Agreement entered into as of October 29, 2009 (Filed With SEC on February 26, 2010)
- Ex-10.3 Amended and Restated Strategic Collaboration and License Agreement effective as of April 28, 2009 between Isis Pharmaceuticals, Inc. and the Registrant (Filed With SEC on August 7, 2009)
- Ex-10.2 License and Collaboration Agreement between the Registrant and Cubist (Filed With SEC on May 8, 2009)
- Ex-10.26 License and Collaboration Agreement (Filed With SEC on March 2, 2009)
- Ex-10.23 Research Collaboration and License Agreement (Filed With SEC on March 2, 2009)
- Ex-10.5 License and Collaboration Agreement, entered into as of September 6, 2007, by and among the Registrant, Isis Pharmaceuticals, Inc. and Regulus Therapeutics LLC (Filed With SEC on November 8, 2007)
- Ex-10.4 Amended and Restated Collaboration Agreement, entered into as of July 27, 2007, by and between the Registrant and Medtronic, Inc (Filed With SEC on November 8, 2007)
- Ex-10.1 License and Collaboration Agreement, entered into as of July 8, 2007, by and among F. Hoffmann-La Roche, Ltd, Hoffman-La Roche Inc., the Registrant and, for limited... (Filed With SEC on November 8, 2007)
- Ex-10.1 Collaboration and License Agreement by and between the Registrant and Biogen Idec MA. Inc. dated September 20, 2006 (Filed With SEC on November 9, 2006)
- EX-10.1 AMEND. & RESTATED RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on August 4, 2006)
- EX-10.1 RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on October 12, 2005)
- EX-10.3 RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on September 12, 2005)
- Ex-10.1 Collaboration Agreement effective as of February 8, 2005 (Filed With SEC on May 16, 2005)
- EX-10.1 COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on August 12, 2004)
- EX-10.24 STRATEGIC COLLABORATION & LICENSE (Filed With SEC on April 6, 2004)
